{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"58","value":"29"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"52","value":"18"},{"comment":"No participant had overall response.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Overall response rate defined as percentage of relapsed/refractory multiple myeloma participants who achieved partial response (PR), complete response (CR) and very good partial response (VGPR) according to International Myeloma Working Group Criteria. PR=\\>50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>90% or \\<200 mg/24 h. If serum and urine M-protein are unmeasurable, \\>50% decrease in difference between involved and uninvolved free light chain levels in place of M-protein criteria. If serum and urine M-protein and serum free light assay are not measurable, \\>50% reduction in plasma cells in place of M-protein, provided baseline bone marrow plasma cell \\>0%; CR=negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow; VGPR=serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\> 90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Normal Renal Function: Ixazomib"},{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Severe Renal Impairment: Ixazomib"},{"description":"After part A the participant has the option to participate in Part B start with ixazomib capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"End-stage Renal Disease: Ixazomib"}],"paramType":"NUMBER","populationDescription":"Response evaluable is defined as participants who received at least 1 cycle of ixazomib treatment in Part B and at least 1 post-baseline response assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 of every other cycle from cycle 1 (each cycle of 28 days) up to progression of disease (approximately up to 855 days)","title":"Percentage of Participants With Overall Response (OR) in Relapsed/Refractory Multiple Myeloma (RRMM) Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}